Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 5183

Drug Profile

IRX 5183

Alternative Names: AGN 195183; NRX 195183; VTP 195183

Latest Information Update: 14 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Developer Io Therapeutics
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Psoriasis
  • Discontinued Stem cell mobilisation

Most Recent Events

  • 14 May 2016 Phase-I/II development for Cancer is ongoing in USA (PO)
  • 22 Apr 2016 Sidney Kimmel Comprehensive Cancer Center plans a phase I/II trial for Acute myeloid leukaemia, Myelodysplastic syndrome and Chronic myelomonocytic leukaemia (Second-line therapy or greater) in USA (PO) (NCT02749708)
  • 06 Oct 2011 Clinical trials in Psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top